Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH.
Lorne J GulaSteve DoucettePeter Leong-SitAnthony S L TangRatika ParkashJean-Francois SarrazinBernard ThibaultVidal EssebagStanley K TungMarc William DeyellJean-Marc RaymondChris LanePablo B NeryGeorge D VeenhuyzenDamian P RedfearnJeffrey S HealeyJean-Francois RouxKaren GiddensJohn L SappPublished in: Journal of cardiovascular electrophysiology (2018)
Patients in the VANISH study randomized to ablation did not have a significant change in quality of life outcomes compared to those randomized to escalated therapy. Some subgroup findings were significant, as those randomized to ablation showed persistent improvement in SF-36 energy/fatigue and ICD concern, and transient improvement in SF-36 social functioning and EQ-5D overall health.
Keyphrases
- double blind
- phase iii
- open label
- placebo controlled
- healthcare
- phase ii
- catheter ablation
- clinical trial
- end stage renal disease
- mental health
- ejection fraction
- radiofrequency ablation
- public health
- newly diagnosed
- heart failure
- prognostic factors
- randomized controlled trial
- study protocol
- type diabetes
- peritoneal dialysis
- bone marrow
- adipose tissue
- physical activity
- health information
- patient reported outcomes
- congenital heart disease
- depressive symptoms
- skeletal muscle
- risk assessment
- sleep quality
- health promotion